The GSDMD Knockout 786-O Polyclonal Cells represent a CRISPR/Cas9-edited polyclonal cell population specifically engineered for loss-of-function analysis of the human GSDMD gene. This product provides a heterogeneous knockout pool in the 786-O cell background, avoiding clonal selection artifacts and preserving biological variability inherent in polyclonal populations. The disruption of GSDMD is achieved through CRISPR/Cas9-mediated gene targeting, generating a versatile model for dissecting pyroptotic pathways without assumptions of complete knockout or monoclonality. This format is well-suited for functional assays requiring native-like cellular contexts and bulk population responses, such as inflammatory cell death studies or high-content phenotypic screens.
The host 786-O cell line is a well-characterized human clear cell renal cell carcinoma (ccRCC) model originally derived from a primary renal clear cell adenocarcinoma. These epithelial cells exhibit a loss-of-function VHL mutation, leading to constitutive stabilization of hypoxia-inducible factors and activation of hypoxia-responsive signaling networks. Consequently, 786-O cells serve as a standard platform for investigating ccRCC biology, tumor microenvironment interactions, and cellular responses to metabolic stress. Their renal origin and genetic background make them particularly relevant for studies linking inflammation and cell death to kidney cancer pathogenesis.
GSDMD (gasdermin D) functions as the principal executioner of pyroptosis, a lytic and highly pro-inflammatory form of programmed cell death. Upon activation of canonical or non-canonical inflammasome pathways, inflammatory caspases such as CASP1, CASP4, and CASP5 cleave GSDMD at a conserved Asp residue, liberating its N-terminal pore-forming domain. This fragment translocates to the plasma membrane, where it oligomerizes and inserts into the lipid bilayer, forming non-selective pores that disrupt osmotic balance and cause cell swelling and rupture. GSDMD is a central downstream effector of supramolecular complexes including NLRP3, NLRC4, and AIM2 inflammasomes, which recruit the adaptor PYCARD (ASC) to facilitate caspase-1 activation. Its pore-forming activity directly mediates the extracellular release of mature IL1B and IL18, along with damage-associated molecules like LDH and HMGB1, thereby amplifying inflammatory cascades.
In the context of 786-O ccRCC cells, GSDMD knockout provides a unique opportunity to study the interplay between pyroptosis and tumor biology. Renal cell carcinoma often exhibits altered inflammatory signaling and can be influenced by immunogenic cell death modalities within the hypoxic tumor microenvironment. Disruption of GSDMD in this background enables dissection of pyroptosis-specific contributions to cytokine secretion, immune cell recruitment, and tumor cell survival. Furthermore, it allows exploration of potential crosstalk between pyroptotic and apoptotic pathways under the influence of oncogenic mutations and hypoxia-driven gene expression programs characteristic of ccRCC.
This GSDMD knockout model is ideally employed for detailed mechanistic studies of inflammasome-dependent pyroptosis in renal cancer. Researchers can utilize it to monitor IL1B and IL18 secretion via ELISA, quantify LDH release as a measure of lytic death, or assess caspase-1 enzymatic activity following canonical NLRP3 stimulation (e.g., with nigericin, ATP, or LPS priming). Complementary approaches include western blotting for cleaved GSDMD fragments, flow cytometry-based propidium iodide uptake for membrane integrity, and immunofluorescence imaging of GSDMD pore formation. The model is also valuable for small-molecule screening aimed at modulating pyroptosis or for investigating the role of GSDMD in tumor-immune interactions within ccRCC. For additional technical information, please contact Ascent Research.
